BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures (FIAS)

Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

Study Overview

• Status: Active, not recruiting
• Conditions: Focal Impaired Awareness Seizures
• Intervention / Treatment: Drug: BIS-001ER

• Study Type: Interventional
• Enrollment (Anticipated): 16
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3050
      • The Royal Melbourne Hospital
    • Melbourne, Victoria, Australia, 3050
      • The Alfred Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Speak English with sufficient proficiency to read and comprehend the Informed Consent document, and to communicate with study staff.
• Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
• Have signed the Informed Consent before any study-specific procedures are performed.
• Be males or females between 18 - 65 years of age.
• Have a diagnosis of FIAS type epilepsy with or without additional focal aware or non-aware seizures with generalization.
• Have a current minimum average of 5 countable seizures / week to enroll in study.
• Have at least 5 focal impaired awareness seizures during the 96-hour baseline VEM period.
• Be receiving stable doses (for at least 4 weeks) of one to four currently marketed anti-epileptic drugs (AEDs), with or without vagus nerve stimulation (in which case the patient should be on the same stimulation parameters for at least 4 weeks).
• Have a negative urinary pregnancy test upon admission to the site on Day 1.
• Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead ECG, and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
• Be able to comply with all study-specified procedures.
• Weight between 40 and 120 kg.

Exclusion Criteria:

• Has taken Huperzine A within the past year.
• Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing.
• Have non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
• Has seizures that are difficult to count; for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
• Have less than the 5 minimum accepted seizures required during baseline evaluation period screen.
• Have a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
• Has attempted suicide within the past 2 years.
• Has a history of status epilepticus in the 6 months previous to enrollment.
• Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the Principal Investigator's opinion, could interfere with the participant's suitability for participation in the study.
• Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
• Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator.
• Is on concomitant therapy with non-AEDs that are cholinergic.
• Has participated in any clinical investigational drug or device study within four weeks prior to study entry.
• Inability to complete seizure diary.
• Is currently taking or has taken Epigallocatechin gallate (EGCG) within the past 14 days, or consume foods or drinks containing EGCG; including green, white, oolong teas and certain black teas, or food containing >100grams of carob powder within the past 14 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: BIS-001ER; Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.

Drug: BIS-001ER; BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.; Other Names: Huperzine A ER

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of BIS-001ER on Seizure Count	Reduction in average daily seizure count between baseline (pre-treatment) and evaluation (on treatment) video EEG monitoring periods.	6 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect of BIS-001ER on Percent Reduction in Daily Seizure Count	Percent reduction in average daily seizure count from the baseline VEM period compared to the evaluation video EEG monitoring period (on treatment).	6 Weeks
Effect of BIS-001ER on Seizure Count vs Titration Period (Diary)	Percent reduction in average number of seizures from the baseline period. (screening/retrospective diary) compared to the last week of the titration treatment period.	6 Weeks
Percent of Treatment Responders	Percent of participants considered treatment responders defined as those with a ≥25%, ≥50%, ≥75% reduction in seizures from the baseline VEM period compared to the VEM treatment evaluation period.	6 Weeks
Effect of BIS-001ER on Seizure Count During Extension Phase	Percent reduction of average number of seizures vs. baseline/retrospective diary at 1, 3, 6, 12 months during the extension period.	12 Months
Complete Seizure Protection	Proportion of subjects with 100% seizure reduction.	6 Weeks
Need for Rescue Medication	Proportion of subjects requiring rescue medication at different dosages.	6 Weeks

Collaborators and Investigators

• Sponsor: Supernus Pharmaceuticals, Inc.
• Investigators: Study Chair: Azmi Nasser, PhD, Supernus Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2018
• Primary Completion (Anticipated): December 30, 2026
• Study Completion (Anticipated): December 30, 2026

Study Registration Dates

• First Submitted: March 12, 2018
• First Submitted That Met QC Criteria: March 21, 2018
• First Posted (Actual): March 23, 2018

Study Record Updates

• Last Update Posted (Actual): August 30, 2022
• Last Update Submitted That Met QC Criteria: August 29, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Seizures; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Enzyme Inhibitors; Neuroprotective Agents; Protective Agents; Cholinesterase Inhibitors; Huperzine A
• Other Study ID Numbers: BNI-02-1b

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No